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prove important in revealing the roles of aggrecanase versus 
MMP aggrecanolysis in the IGD of aggrecan at different stages 
of human OA. 
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Aim of study: To determine the bone alkaline phosphatase 
(BAP) concentrations in the synovial fluid and serum from horses 
with osteochondral fragmentation compared to normal, treadmill- 
exercised horses. 
Methods: Synovial fluid was collected from the carpal joints and 
blood was collected from the jugular vein of 9 mature Thorough- 
bred horses presented for arthroscopic debridement of osteo- 
chondral fragmentation. As a comparable xercise control group, 
serum and carpal synovial fluid samples were collected from 
14 mature Thoroughbred horses after 6 weeks of regular tread- 
mill training. BAP concentrations were measured in the synovial 
fluid and serum using a commercially available immunoassay 
(Metra TM BAP, Quidel Corporation, San Diego, CA). Synovial fluid 
and serum were compared between the osteochondral fragment 
group of horses and the exercise control group using an unpaired 
t-test. A value of P<0.05 was considered significant. 
Results: The synovial fluid BAP concentration was significantly 
elevated (P<0.01) in the horses with osteochondral fragments 
(mean 4- standard deviation, 21.87 4- 8.4 U) compared to the ex- 
ercise control horses (13.32 4- 6.44 U). However, the serum BAP 
concentration was significantly lower (P<0.001) in the horses 
with osteochondral fragments (31.45 4- 8.44 U) compared to the 
exercise control horses (52.33 4- 11.64 U). 
Conclusions: The elevated concentrations of BAP in the syn- 
ovial fluid of horses with osteochondral fragments compared to 
exercise control horses may be due to local production and re- 
lease of the enzyme from the exposed subchondral bone and 
inflamed synovium. In addition, delayed clearance of BAP from 
the joint as a result of joint effusion may also result in greater 
synovial fluid concentrations. The lower concentrations of BAP in 
the serum of horses with osteochondral fragmentation compared 
to exercise control horses may be due to the basic physiologic re- 
sponse of bone to exercise compared to injury. In the uninjured, 
exercised horse, bone formation (modeling) predominates to ad- 
just to the loads applied during exercise. However, when acute in- 
jury to the bone occurs, as with osteochondral fragmentation, the 
bone may go through a remodeling process. If so, the bone must 
first go through a resorptive period before the osteoblasts would 
be recruited to the site to initiate new bone formation. Therefore, 
due to this relatively delayed response of the osteoblasts, the 
serum BAP concentrations may be lower in the osteochondral 
fragmentation horses compared to horses with exercise-induced 
modeling. Examination of both the synovial fluid and serum BAP 
concentrations in various types of joint disease is valuable in de- 
termining the different local and systemic effects that occur in re- 
sponse to the joint disease. 
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The ability to quantitate aggrecan fragments and their neoepi- 
topes in both plasma and synovial fluids is important for the devel- 
opment of biomarkers that will monitor aggrecan degradation in 
osteoarthritis. While the ultimate goal of these biomarker efforts is 
the development of high sensitivity, reproducible assays capable 
of evaluating large number of clinical and preclinical samples, it is 
essential that these results can be independently validated using 
different echnology to insure the specificity of the immunoassays 
under development. Accordingly, the present study has focused 
on the detection of aggrecan fragments by Western blot analysis 
using two color infrared imaging technology. Initial studies have 
focused on the detection of a 32 amino acid peptide fragment (32- 
mer) following aggrecan digestion with matrix metalloprotease 13 
and ADAMTS 4/5. A rabbit affinity purified polyclonal with recog- 
nition of the carboxy terminus and a mouse monoclonal recogniz- 
ing the amino terminus of the peptide were used to detect the 32- 
mer by Western blot analysis following SDS gel electrophoresis 
of the aggrecan digests. The fluorochrome conjugated detection 
antibodies (anti rabbit and anti mouse) were chosen based on the 
780 and 680 excitation wavelengths of the Odyssey's two diode 
lasers. This technology insures the specificity of the antibodies 
used for higher throughput assays by requiring co-staining with 
both antibodies to the aggrecan peptide of interest and is eas- 
ily visualized in the same sample lane. The ability to utilize this 
approach in complex biologic matrices will provide a greater un- 
derstanding of both neoepitope levels as well as the potential size 
diversity of the neoepitope containing aggrecan fragments in both 
clinical and preclinical samples. 
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The cleavage of aggrecan by aggrecanases (e.g. ADAMTS-4/5) 
generates a series of neoepitope xposed fragments which are 
thought to be potential candidates for Osteoarthritis (OA) asso- 
ciated biomarkers. The ability to detect these neoepitope frag- 
ments in patient samples could potentially aid physicians and re- 
searchers in providing additional criteria in conjunction with clin- 
ical signs for selecting the most appropriate and effective treat- 
ments for symptom amelioration or disease modification. In the 
present study, a series of competitive nzyme-linked immunoab- 
sorbent assays (ELISAs) have been developed to quantitate OA 
biological samples for the most abundant neoepitope fragments 
using affinity purified rabbit polyclonal antibodies (poABs) de- 
rived following synthetic peptide immunizations. These antibod- 
ies were characterized by BIACORE analysis with KD values for 
the specific neoepitope sequences between 10-1° to 10-8M. In 
the competitive ELISA format, the assay measures the ability of 
